Elsevier

Clinical Therapeutics

Volume 30, Issue 10, October 2008, Pages 1918-1931
Clinical Therapeutics

Validation of the spanish version of the asthma control questionnaire

https://doi.org/10.1016/j.clinthera.2008.10.005Get rights and content

Abstract

Background: The Asthma Control Questionnaire (ACQ) has not been validated in the Spanish population, and the fact that it requires spirometry poses an important limitation on its widespread use in the primary care setting in Spain.

Objective: The aim of this study was to evaluate the psychometric properties of the Spanish version of the ACQ.

Methods: In this multicenter, prospective study, consecutive adult patients with persistent asthma were recruited at 62 respiratory and allergy units across Spain. Patients were assessed at baseline and at weeks 2 and 6. The following clinical variables were recorded: lung function (forced expiratory volume in 1 second [FEV1]), symptoms, exacerbations, concomitant diseases, asthma severity according to the Global Initiative for Asthma international guideline, and asthma control as perceived by patients and physicians through direct ad hoc questions. The latter measures were derived specifically for this study. Patients self-completed the ACQ at all visits before the rest of the study variables were recorded. The ACQ's feasibility, validity, reliability, and sensitivity to change were assessed. Cross-sectional and longitudinal validity was assessed using the relationship between ACQ score and clinical parameters. Sensitivity to change was assessed by estimating the global effect size and the minimal important difference (MID). Reliability was assessed using estimation of the Cronbach α coefficient (CCα) and intraclass correlation coefficient (ICC).

Results: A total of 607 patients were included. The mean (SD) age was 45.6 (17.1) years and 61.4% of the patients were women. Of these 607, 235 (39%) had mild asthma; 246 (41%), moderate; and 126 (21%), severe. Mean (SD) time to complete the ACQ was 3.9 (4.4) minutes. The Pearson correlation coefficient in the relationship between ACQ and FEV1 (% predicted value) was -0.23. ACQ was found to be significantly related to asthma severity and intensity and frequency of symptoms (coughing, wheezing, and dyspnea) (both, P < 0.001). Change in ACQ was significantly related to changes in FEV1, intensity and frequency of symptoms, and number of exacerbations (all, P < 0.001). The global effect size of ACQ was 0.46 and the MID was 0.47 point of a maximum of 6. CCα was 0.90 and ICC was 0.86.

Conclusion: In these adults with asthma in Spain, the Spanish version of the ACQ was found to be a reliable and valid questionnaire, suggesting that it can be used in this population as a discriminative and evaluative instrument.

References (33)

  • JK Sont

    How do we monitor asthma control

    Allergy.

    (1999)
  • ED Bateman

    Measuring asthma control

    Curr Opin Allergy Clin Immunol.

    (2001)
  • LP Boulet et al.

    How should we quantify asthma control. A proposal

    Chest.

    (2002)
  • ED Bateman et al.

    Achieving guideline-based asthma control: Does the patient benefit

    Eur Respir J.

    (2002)
  • FL Urbano

    Review of the NAEPP 2007 Expert Panel Report (EPR-3) on Asthma Diagnosis and Treatment Guidelines

    J Manag Care Pharm.

    (2008)
  • AW Green et al.

    Improving asthma management: One health plan's experience

    Am J Manag Care.

    (2007)
  • Cited by (42)

    • Asthma in adults: What's new?

      2023, FMC Formacion Medica Continuada en Atencion Primaria
    • Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis

      2023, Journal of Allergy and Clinical Immunology
      Citation Excerpt :

      Moreover, unexplained superior ACQ score improvement of mepolizumab despite poor efficacy in improving lung function observed in this meta-analysis raises the concern that ACQ score might not capture important improvements based on pathophysiology. One possible explanation was that the included RCTs used either ACQ-5 or ACQ-6, which do not include the objective question on FEV1 accounting for the weak-to-moderate correlation between these ACQ versions and FEV1,46,47 in spite of the moderate-to-strong correlation between ACQ-7 and FEV1.48 However, the ACQ score is an important outcome, albeit subjective, because it captures a patient’s assessment of their own asthma control.

    • Bronchial asthma

      2022, Medicine (Spain)
    View all citing articles on Scopus
    *

    Members of the Covalair Investigator Group are listed in the Acknowledgments.

    View full text